279 related articles for article (PubMed ID: 20424485)
21. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
22. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M
Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036
[TBL] [Abstract][Full Text] [Related]
23. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
Wang F; Li M; Cheng L; Zhang T; Hu J; Cao M; Zhao J; Guo R; Gao L; Zhang X
Life Sci; 2008 Dec; 83(25-26):828-35. PubMed ID: 18983856
[TBL] [Abstract][Full Text] [Related]
24. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
25. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
[TBL] [Abstract][Full Text] [Related]
26. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis.
Ndisang JF; Jadhav A
Endocrinology; 2014 Jan; 155(1):215-29. PubMed ID: 24140713
[TBL] [Abstract][Full Text] [Related]
27. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Tominaga N; Robert A; Izuhara Y; Ohtomo S; Dan T; Chihara K; Kurokawa K; Van Ypersele de Strihou C; Miyata T
Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
[TBL] [Abstract][Full Text] [Related]
28. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
[TBL] [Abstract][Full Text] [Related]
29. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of diabetic nephropathy by Chaihuang-Yishen granule through anti-inflammatory mechanism in streptozotocin-induced rat model of diabetics.
Zhang H; Zhao T; Gong Y; Dong X; Zhang W; Sun S; Wang H; Gu Y; Lu X; Yan M; Li P
J Ethnopharmacol; 2014; 151(1):556-64. PubMed ID: 24269779
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Kelly DJ; Cox AJ; Tolcos M; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Kidney Int; 2002 Jan; 61(1):31-9. PubMed ID: 11786082
[TBL] [Abstract][Full Text] [Related]
33. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
34. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Awad AS; Webb RL; Carey RM; Siragy HM
J Hypertens; 2004 Aug; 22(8):1571-7. PubMed ID: 15257181
[TBL] [Abstract][Full Text] [Related]
35. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat.
Kelly DJ; Skinner SL; Gilbert RE; Cox AJ; Cooper ME; Wilkinson-Berka JL
Kidney Int; 2000 May; 57(5):1882-94. PubMed ID: 10792607
[TBL] [Abstract][Full Text] [Related]
36. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
37. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
[TBL] [Abstract][Full Text] [Related]
38. Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats.
Wiggins KJ; Tiauw V; Zhang Y; Gilbert RE; Langham RG; Kelly DJ
Nephrology (Carlton); 2008 Dec; 13(8):721-9. PubMed ID: 18826488
[TBL] [Abstract][Full Text] [Related]
39. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
40. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
